These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 23204495)

  • 1. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer.
    Oh JS; Kang BC; Roh JL; Kim JS; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Aug; 22(8):2746-54. PubMed ID: 25487968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
    Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
    PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma.
    Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC
    J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
    Ohri N; Duan F; Snyder BS; Wei B; Machtay M; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M; El Naqa I
    J Nucl Med; 2016 Jun; 57(6):842-8. PubMed ID: 26912429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
    Bahce I; Vos CG; Dickhoff C; Hartemink KJ; Dahele M; Smit EF; Boellaard R; Hoekstra OS; Thunnissen E
    Lung Cancer; 2014 Aug; 85(2):205-12. PubMed ID: 24854401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
    Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.